Akademik Veri Yönetim Sistemi
ECTRIMS 2022, Amsterdam, Hollanda, 26 - 28 Ekim 2022, cilt.28, sa.821, ss.860
Introduction: Ocrelizumab is an effective treatment in reduc-ing relapse rate and slowing disability progression in the short term.Aims:To evaluate disability progression in people with multiple sclerosis (pwMS) treated with ocrelizumab.Methods: pwMS candidates for ocrelizumab treatment were enrolled in this prospective single-center observational study and followed up for two years. Disability was evaluated with Expanded Disability Status Scale (EDSS), Timed 25 Feet Walk (T25F) test, 9 Hole Peg Test (9HPT), Timed up and Go (TUG) test, and Twelve Item MSWalking Scale (MSWS) survey. First assessments were done before the ocrelizumab initiation and every six months after-ward. Patients with secondary progressive and primary progres-sive MS were analyzed as progressive MS (PMS). A change of %20 in test performance time was considered clinically significant.Results: 107 PMS patients were enrolled. When analyzed sepa-rately, there was no significant difference between baseline and two-year follow-up scores in total EDSS and functional subscores (p>0.05). PMS showed significant worsening in the TUG test (p=0.043) in the first, T25FW (p=0.03) in the second, and MSWS-12 scores in the first (N:99, p:0,006) and the second (N:43 p:0.002) years of evaluation in comparison to baseline results. Of 53 PMS evaluated in the second year, 39 had not shown significant change on 9HPT results, two had improved performance, and 12 had a %20 increase in the test time compared to baseline. Overall 9HPT results did not show a significant change in two-year follow-up (p>0.05).Conclusions: Although ocrelizumab does not show favorable results in the lower extremity functions in the progressive form, it could halt the disability accumulation in the upper extremity in the long term. Disclosure Cavid Baba: nothing to disclose Ergi Kaya: nothing to disclose Sinem Ozcelik: nothing to disclose Asiye Tuba Ozdogar: nothing to disclose Ozge Sagici: nothing to disclose Seda Dastan: nothing to disclose Serkan Ozakbas: nothing to disclose